Nasus Pharma Ltd
NSRX NYSE· Pharmaceutical Preparations
Last close · Oct 26, 2026
$3.49
KIRA · Stoqly’s AI analyst, in plain words
- Nasus Pharma Ltd had $1.2B of revenue in fiscal 2025.
- Its operating margin was −0.4%: of every 100 in sales, about −0 is left after running the business.
- Nasus Pharma Ltd lost $5.9M in fiscal 2025.
- Free cash flow was −$4.9M in fiscal 2025, −0.4% of revenue.
Market cap
$28.0M
P/E
—
Revenue
$1.2B
Net income
−$5.9M
Free cash flow
−$4.9M
Operating margin
−0.4%
Nasus Pharma Ltd in 30 seconds · fiscal 2025
Does it make a profit?
−0.5%
No. It lost money last year.
Does profit turn into cash?
−0.4%
No. It spent more cash than it brought in.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Nasus Pharma Ltd does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 25, 2026
- Legal name
- Nasus Pharma Ltd
- CIK
- 0002029039
Nasus Pharma Ltd · NSRX
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | — | — | $1.2B |
| Operating margin | — | — | −0.4% |
| Net income | −$1.1M | −$1.5M | −$5.9M |
| Net margin | — | — | −0.5% |
| Diluted EPS | −$0.20 | −$0.22 | −$0.72 |
| Cash | |||
| Cash from operations | −$1.0M | −$0.7M | −$4.9M |
| Capital expenditure | — | — | $0.0M |
| Free cash flow | — | — | −$4.9M |
| FCF margin | — | — | −0.4% |
| Share count change | — | −0.4% | 14.0% |
| Debt and strength | |||
| Cash and short-term investments | $0.2M | $0.3M | $1.2M |
| Shareholders' equity | −$3.8M | −$3.2M | $2.8M |
| Current ratio | — | 0.1x | 2.2x |
| Interest coverage | −23.4x | −37.2x | — |
| Returns and quality | |||
| Return on tangible equity | — | — | 211.6% |
| Altman Z'' | — | −100.3 | −13.8 |
Insiders bought, 12 months
$0.1M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Nasus Pharma Ltd · NSRX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.49 a share, the company is worth $28.0M.
Source: SEC EDGAR XBRL filings (CIK 0002029039). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.